1. Home
  2. STVN vs ABVX Comparison

STVN vs ABVX Comparison

Compare STVN & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • STVN
  • ABVX
  • Stock Information
  • Founded
  • STVN 1949
  • ABVX 2013
  • Country
  • STVN Italy
  • ABVX France
  • Employees
  • STVN N/A
  • ABVX N/A
  • Industry
  • STVN Containers/Packaging
  • ABVX
  • Sector
  • STVN Consumer Discretionary
  • ABVX
  • Exchange
  • STVN Nasdaq
  • ABVX Nasdaq
  • Market Cap
  • STVN 7.4B
  • ABVX 6.7B
  • IPO Year
  • STVN 2021
  • ABVX N/A
  • Fundamental
  • Price
  • STVN $24.66
  • ABVX $92.67
  • Analyst Decision
  • STVN Buy
  • ABVX Strong Buy
  • Analyst Count
  • STVN 4
  • ABVX 10
  • Target Price
  • STVN $25.13
  • ABVX $103.80
  • AVG Volume (30 Days)
  • STVN 355.2K
  • ABVX 1.1M
  • Earning Date
  • STVN 11-04-2025
  • ABVX 08-11-2025
  • Dividend Yield
  • STVN 0.26%
  • ABVX N/A
  • EPS Growth
  • STVN 6.78
  • ABVX N/A
  • EPS
  • STVN 0.57
  • ABVX N/A
  • Revenue
  • STVN $1,344,798,591.00
  • ABVX $7,073,400.00
  • Revenue This Year
  • STVN $8.33
  • ABVX $4.44
  • Revenue Next Year
  • STVN $10.12
  • ABVX N/A
  • P/E Ratio
  • STVN $41.95
  • ABVX N/A
  • Revenue Growth
  • STVN 5.28
  • ABVX N/A
  • 52 Week Low
  • STVN $17.12
  • ABVX $4.77
  • 52 Week High
  • STVN $28.00
  • ABVX $98.64
  • Technical
  • Relative Strength Index (RSI)
  • STVN 48.72
  • ABVX 65.30
  • Support Level
  • STVN $23.01
  • ABVX $85.00
  • Resistance Level
  • STVN $24.83
  • ABVX $98.59
  • Average True Range (ATR)
  • STVN 1.29
  • ABVX 3.87
  • MACD
  • STVN -0.15
  • ABVX 0.09
  • Stochastic Oscillator
  • STVN 40.34
  • ABVX 64.53

About STVN Stevanato Group S.p.A.

Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables and its other segment is Engineering. Geographically, the company derives majority revenue from Europe, Middle East and Africa.

About ABVX Abivax SA American

Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.

Share on Social Networks: